Evidence map›Paper›PMID 28827754›Full record

ArticleScientific reports2017

T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART.

Yonas Bekele, Desalegn Yibeltal, Kidist Bobosha, Temesgen E Andargie, Mahlet Lemma, Meseret Gebre, Eyasu Mekonnen, Abiy Habtewold, Anna Nilsson, Abraham Aseffa and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Protein/AS01Cell reports. Medicine · 2021
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yonas BekeleDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Desalegn YibeltalArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Addis Ababa, Ethiopia.
Kidist BoboshaArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Addis Ababa, Ethiopia.
Temesgen E AndargieArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Addis Ababa, Ethiopia.
Mahlet LemmaArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Addis Ababa, Ethiopia.
Meseret GebreAll Africa Leprosy, Tuberculosis and Rehabilitation Training (ALERT) center, Addis Ababa, Ethiopia.
Eyasu MekonnenDepartment of Pharmacology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Abiy HabtewoldDepartment of Pharmacology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Anna NilssonDepartment of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden.
Abraham AseffaArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Addis Ababa, Ethiopia.ORCID 0000-0002-8028-1150
Rawleigh HoweArmauer Hansen Research Institute (AHRI), P.O. Box 1005, Addis Ababa, Ethiopia.
Francesca ChiodiDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. francesca.chiodi@ki.se.
Armauer Hansen Research Institute · ETKarolinska Institutet · SEAddis Ababa University · ETAll Africa Leprosy Tuberculosis and Rehabilitation Training Centre · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HBV vaccine has 95% efficacy in children to prevent HBV infection and related cancer. We conducted a prospective study in HIV-1 infected children receiving ART (n = 49) and controls (n = 63) to assess humoral and cellular responses to HBV vaccine provided with three doses under an accelerated schedule of 4 weeks apart. At 1 month post-vaccination all children, except 4 HIV-1 infected, displayed protective antibody (ab) titers to HBV vaccine; ab titers were lower in infected children (P < 0.0001). Ab titers decreased (P < 0.0001) in both HIV-1 infected and control children at 6 months. The frequency of circulating Tfh (cTFh) cells was 20.3% for controls and 20.8% for infected children prior to vaccination and remained comparable post-vaccination. Cytokine expression by cTfh cells upon activation with HBV antigen was comparable in the two groups at baseline and 1 month post-vaccination. Higher plasma levels (P < 0.0001) of CXCL13 were found in infected children which correlated with cTfh cell frequency at baseline. In conclusion, a lower ab response to HBV vaccine was measured in HIV-1 infected children. The frequency and activation profile of cTfh cells was comparable in infected children and controls suggesting that cells other than Tfh cells are responsible for impaired ab response to HBV vaccine.

Indexed as

Anti-HIV AgentsCase-Control StudiesChildChild, PreschoolCytokinesDrug Administration ScheduleFemaleHepatitis BHepatitis B AntibodiesHepatitis B VaccinesHepatitis B virusHIV-1HIV InfectionsHumansLymphocyte CountMaleAnti-HIV AgentsCytokinesHepatitis B AntibodiesHepatitis B Vaccines

Identifiers

PMID28827754
PMCPMC5566956
OpenAlexW2750012661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.